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SUMMARY 
A critical review of the original literature has been made to identify drugs and 
other substances which interfere chemically with clinical laboratory test procedures. 
The nature and extent of such interference has been correlated with particular meth- 
ods of analysis. 
Medications may alter laboratory test values through a variety of pharmacolo- 
gical, physical or chemical mechanisms. Phal/macologically, a drug may cause a true 
change in the concentration of the particular substance being measured. Thus, allo- 
purinol, a xanthine oxidase inhibitor, is used to reduce plasma uric acid levels in 
selected patients. Incidental pharmacologic effects, other than those primarily in- 
tended, may also occur. Antiovulatory drugs, used for contraceptive purposes, cause 
an increase in total serum thyroxine-binding globulin. This results in an increase in 
both total serum thyroxine and unsaturated thyroxine-binding globulin, but no sig- 
nificant change in unbound (“free”) thyroxine. Recognition of these effects is essential 
in the interpretation of thyroid function tests. Drugs may also cause undesirable toxic 
or side effects, as evidenced by changes in liver or renal function tests. Thus, in some 
individuals, phenothiazines will produce a picture of obstructive jaundice, with eleva- 
tion in serum bilirubin and alkaline phosphatase. Knowledge of the pharmacologic 
effects of drugs helps to explain a number of correct but otherwise unexpected 
laboratory results. Several reviews, dealing primarily with such changes, have ap- 
peared recently1-3. 
Chemically, a drug or its metabolite may interfere with the accurate determina- 
tion of the desired constituent. For example, methyldopa, used in the treatment of 
hypertension, will produce a false positive result for urinary catecholamines, since it 
reacts in the method to produce a green fluorescence similar to that produced by 
norepinephrine. This could lead to an erroneous diagnosis of pheochromocytoma. 
Radiographic contrast media, containing iodinated organic compounds, invalidate 
protein-bound iodine determinations because of their own high iodine content. Other 
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drugs can interfere by producing extraneous color reactions, by chelation, or by in- 
hibition of enzyme activity. 
In addition to chemical interferences by drugs, one should also consider the 
effects of anticoagulants and of marked changes in concentrations of normally occur- 
ring substances in body fluids which alter laboratory test values. Hemolysis, lipemia, 
and elevated serum bilirubin interfere in a number of procedures. In uremia, associated 
high levels of creatinine and uric acid can result in falsely elevated values for glucose 
as measured by alkaline ferricyanide methods. 
Chemical interferences arise primarily from lack of specificity of the methods 
used to measure desired constituents. The usual methods of quality control, such as 
including a control serum or standard with each series of determinations, will not 
detect errors arising from some interfering substance in one of the unknowns. This 
problem of specificity is an area of special concern to the clinical chemist. 
In 1968, Elking and Kabat4 tabulated over 1500 citations relevant to drug- 
induced modifications of laboratory test values. Garb5, in a recent book, includes this 
and additional information in handy tabular form. Martine, in his text, also includes 
tables on drug interference with clinical laboratory tests. These valuable contribu- 
tions list the effects of drugs as resulting either in an elevated (or false positive) value 
or a decreased (or false negative) value but do not distinguish, for the most part, be- 
tween pharmacologic effects and chemical interferences. An exception is the work 
of HanstenT, who presents discussions concerning the effects of drugs on clinical labo- 
ratory test values and distinguishes those in which the effect is due to interference 
with the testing procedure. 
Another problem is to determine whether a reported drug interference was ob- 
served at realistic concentrations which are likely to occur in serum or urine during a 
typical therapeutic regimen. We have found, for example, that methyldopa, in con- 
centrations of IO mg/dl, will cause spurious elevations of results obtained in the de- 
termination of uric acid. The usual dosage schedule for methyldopa, however, leads 
to plasma concentrations of approximately 0.2 mg/dl and urine concentrations of 
approximately IO-z5 mg/d18. At these levels, interference with determinations on 
urine is substantial but for serum it is insignificant. 
Several approaches have been used to investigate the effects of drugs on labora- 
tory test values. Naumann9 studied the effect of a single drug, phenazopyridine (Pyri- 
dium), on a number of procedures. O’Kell et aLIO added antibiotics to serum to ap- 
proximate levels likely to be encountered in patients and found no interference in 
IZ automated methods of analysis. Singh et al.ll, analyzed solutions of 45 medications, 
at I mmole/liter concentrations, on the Technicon SMA 12/60 and found significant 
interference from 25. Of these, 8 showed significant interference at concentrations 
likely to occur in plasma after a single maximum therapeutic dose. With a screening 
battery of g tests, Van Peenen and Files I2 found negligible differences in test results 
from a series of 2500 patients either receiving or not receiving 42 commonly adminis- 
tered medications. These findings, of course, apply only to the test procedures and 
medications studied. Cryer and Sode13 investigated a number of analgesics and tran- 
quilizer-sedatives to determine those which could be used during diagnostic evaluation 
of adrenal function without pharmacologic or chemical alteration of urinary hormonal 
values. Borushek and Gold14, in a classic study, determined the effects of 23 drugs on 
values for urinary IT-ketosteroids and r7-hydroxycorticosteroids. These drugs were 
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tested in pure solution and in combination with pure standards. In addition, they 
were administered to patients to determine the change in test values on z4-hour urine 
collections. All of these various approaches have merit and could be expanded to in- 
clude more medications and different methods of analysis. 
In the present study, a critical review of the original literature has been made 
with respect to chemical interferences in clinical laboratory test procedures. Attention 
has been directed especially to the methods employed and, where possible, to the 
nature and extent of such interferences. Ready availability of this information should 
help to explain certain anomalous test results and stimulate development or adoption 
of more specific methods of analysis. 
TABULATIONS 
The information is arranged alphabetically according to test procedures. Sub- 
headings, describing the analytical method affected, are followed by alphabetical list- 
ings of interfering substances. The latter are preceded by the notation (+) or (-) to 
indicate that the substance causes a false increase or false decrease, respectively, in 
test values. A substance reported to show no interference with the test is preceded by 
the notation (0). References are given to the original literature, but no claim is made 
for complete coverage. Some selection in choice of citations has been exercised, when 
multiple observations in substantial agreement have been reported. In some cases, 
we have augmented the material with personal observations or experiments and these 
have been so indicated. 
Interferences from bilirubin, hemoglobin, lipemic serum, color of urine, etc., 
cause obvious problems with various spectrophotometric or visual examinations. 
Chemical interferences from these sources have not been listed, unless special circum- 
stances seemed to warrant them. Interferences from impurities in reagents or distilled 
water have not been included, with a few exceptions, inasmuch as these can normally 
be detected or corrected by inclusion of reagent blanks, standards, and recovery ex- 
periments. 
Drugs are listed by generic name, followed, in some cases, by the more common 
brand name or names. This information has been taken from Facts and Comparisonsl5, 
updated to 1972. This publication is very convenient for such cross-referencing. 
AMYLASE 
The following anticoagulants are reported to reduce plasma amylase activity 





A. Screening tests on sewma OY urine depend upon the formation of mercuric salts 
which are soluble in chloroform. Addition of dithizone (diphenylthiocarbazone) results 
in a change of color from blue to orange if barbiturates are presentls. With diphenyl- 
czin. Chim. Acta, 41 (1972) 395-434 
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carbazone, the color change is from red to deep purplelQ. Our own observations are 
based on the latter procedure. 
(+) Chlordiazepoxide (Librium). We have observed false positives with toxic over- 
doses only. 
(+) Chlorpheniramine lg. Interferes only at toxic levels (over 4 mg/dl). 
(+) Diazepam (Valium). We have observed false positives with toxic overdoses only. 
(+) Diphenylhydantoin 18. Reported to give a positive reaction at a concentration of 
8 mg/dl. 
(+) Glutethimide (Doriden)18. Reported to give a positive reaction at a concentration 
of 5 mg/dl. 
(+) Meperidine (Demerol). We have observed false positives in patients receiving the 
drug and in vitro at concentrations of IO mg/dl. 
(+) Methyprylonls. Interferes only at toxic levels (over 150 mg/dl). 
(+) Tin. May be present in filter paper 20. Reacts with diphenylcarbazone to produce 
a deep purple color. 
(+) Tolbutamide. We have observed false positives in patients receiving the drug 
and in vitro at concentrations of IO mg/dl. 
B. Ultraviolet s$ectrophotometric methods based on absorbance readings at 239 nm 
at pH IO and on decrease in absorbance after acidification. 
(-) Salicylate. Extracted with barbiturates and shows an increase in absorbance after 
acidification. Suitable corrections can be madezl. 
BILIRUBIN 
A. Sewna bilirubin is determined by reacting it with diazotized sulfanilic acid 
to produce reddish-violet azobilirubin. In the Malloy-Evelyn method, the final mix- 
ture is acid and contains 50% methanol. A serum blank is included routinely. 
(+) Dextran 22. Used as a plasma expander and produces turbidity in presence of 
methanol. Serum blanks tend to be variable and do not provide adequate correc- 
tion. 
(-) Hemoglobin 23. Nitrite converts hemoglobin to methemoglobin. Decreased values 
for bilirubin may be related to competition for nitrite between hemoglobin and 
sulf anilic acid. 
B. Direct spectrophotometric estimation of biliwbin. Readings are made at 2 
wavelengths to correct for absorbance by hemoglobin. Single readings at one wave- 
length (usually 460 nm) are reported in terms of “icterus ind.ex”. 
(+) Carotene. This pigment is normally present in serum and appears in excess after 
ingestion of large amounts of carrots or other yellow-colored vegetables. 
(+) Hemoglobin. Causes spurious elevation in icterus index, especially if readings 
are made at 420 nm rather than 460 nmz4. 
(+) Lipemia. Contributes to absorbance and is not corrected by reading at 2 wave- 
lengths since the apparent absorbance of turbid solutions increases as wavelength 
is decreased. 
(+) Novobiocin. A yellow lipochrome metabolite of the drug appears in plasmaZ5. 
C. Bilimbin ia wine is detected by reaction with an acidified diazonium com- 
pound, available in tablet or test strip form, to produce a blue to purple color (e.g., 
Ictotest, Ames Co.). 
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({-) Ethoxazene (Serenium). Colors the urine orange-red and may be misinterpreted 
as positive for bilirubin. 
(+) Phenazopyri~ne (Pyridium). Colors the mine orange-brown and becomes red- 
dish-brown in acid solution. May be misinterpreted as positive for bilirubin@. 
BLOOD, OCCULT 
This determination is done on urine or feces to detect amounts of bIood not 
grossly visible. Hemoglobin, myoglobin, and hematin exhibit peroxidase-hike activity 
which, in the presence of hydrogen peroxide effects oxidation of various substrates 
such as guaiac, benzidine, and o-tolidine to produce color. Peroxidases from other 
sources may be removed by boiling the specimen. Various tablets and reagent strips 
have been formulated to improve stability of the reagents. Sensitivity, effects of diet, 
and iron salt therapy have been reviewed26. 
(-) Ascorbic acid. Competes with chromogen. Levels in urine exceeding 50 mg/dl 
inhibit the reaction. 
(+) Bacteria. Old urine specimens may show peroxidase activity associated with 
excess growth of certain bacteria. 
(+) Bromide. Reacts in. vitro but is unlikely to be present in urine or feces in quanti- 
ties sufficient to produce false positivesZ7. 
(+) Iodide. Same reaction as bromide2’. 
(+) Iron salts. Feces are colored black. May show false positive with guaiac test if 
tannic acid is present as a contaminant in the reagents7. 
(+) Methyldopa. Patients receiving this drug do not show a color change in the urine. 
Specimens collected in containers cleaned with bleach (hypochlorite) may turn 
reddish-brown immediately, giving a false impression of blood in the urine28. 
(+) Sulfobromophthalein (BSP). Alkaline stools may appear “bloody”but tests for 
occult blood are negativeas. 
(-) Tetracyclines. Some preparations contain high concentrations of ascorbic acid as 
preservative. Large amounts in the urine inhibit color development. 
BSP TEST 
S~fobromophthal~in (BSP) is injected intravenously, usually in doses of 5 
mg{kg of body weight, as a test of liver function. Blood is drawn after 45 min, and the 
serum made alkaline to develop the color of the remaining BSP. Increased values are 
observed in liver disease, due to failure of conjugation or excretion by the liver. 
(+) Anabolic steroids (e.g., norethandrolone). These appear to affect liver function as 
evidenced by concurrent increase in serum lactic dehydrogenase or bilirubin~331. 
(+) Iopanoic acid (Telepaque). This and other radiographic contrast media compete 
with BSP for excretion by the liver 90~32,33. The two tests should not be performed 
at the same time. 
(-) Phenazopyridine (Pyridium). Methods in which acidified serum blanks are used 
produce low results since the drug produces a pink color in acid solution. A pre- 
injection alkalinized serum blank is recommended?‘. 
(+) P~enolsulfonpbthalein (PSP). Used as a test of kidney function and produces 
similar color in alkaline solution; hence, the two tests should not be performed 
at the same time. 
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CALCIUM 
Methods for determining calcium in biologic materials have been reviewed re- 
cently by Martinek34. 
A. Emission spectro$hotometry (flame photometry) . This method of analysis has 
not gained much favor in the clinical laboratory, owing to relatively low concentra- 
tions of calcium in serum, high temperature flame requirements, and interference by 
various substances. 
(+) Sodium35p36. Enhances the calcium signal. Excess sodium is added to both stan- 
dards and unknowns to minimize effect. 
(-) Phosphate35J7*38. The depressant effect can be minimized by adding phosphate 
to standards. 
B. Atomic absorption, spectrophotometry. The following substances are reported 
to depress observed values for serum calcium, but the effect can be counteracted 
(except for protein) by adding lanthanum chloride to standards and unknowns39. 
(-) Edetate (EDTA). 
(-) Oxalate. 
(-) Phosphate. 
(-) Protein. Compensate by adding protein to standards. 
(-) Sulfate. 
C. Preci$itation of calcium with oxalate. The precipitate is washed to remove 
excess oxalate, dissolved in acid, and titrated with potassium permanganate under 
controlled conditions. 
(-) Edetate (EDTA). May be present in serum from patients treated with EDTA. 
The serum should be acidified to pH 3-5 before precipitating calcium with 
oxalate40. 
(0) Magnesium. No magnesium oxalate is precipitated provided the pH is less than 
7.041. 
D. Methods dependent u$o?a titration of calcium ions with EDTA, using various 
calorimetric or fluorometric endpoints, or upon direct spectrophotometric determina- 
tions based on production of color with suitable calcium indicators in alkaline solu- 
tion. A wide choice of indicators and final working conditions have been used. Actual 
degree of interference from the following substances must be determined for the partic- 
ular method employed. 
(-&) Bilirubin. May interfere with endpoint detection in titrimetric methods. Con- 
tributes to absorbance in photometric methods. 
(-) Citrateat. Chelates calcium ions. May be present in serum following transfusions 
of titrated blood. 
(+) Copper (II). Unlikely to be present in significant concentrations in biological 
fluids. Addition of cyanide overcomes interference43+. 
(-) Edetate (EDTA). Chelates calcium ions. May be present in serum from patients 
treated with EDTA. 
(+) Iron (II). Unlikely to be present in significant concentrations in biological fluids. 
Addition of cyanide overcomes interference43944. 
(+) Magnesium. Interference depends on specificity of the indicator for calcium and 
on pH of final reaction mixture. 
(-) Phosphate. Complexes calcium ions. Extent of interference depends on relative 
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and absolute concentrations of calcium and phosphate ions. Interference is more 
common in determinations on urine,owing the high phosphate levels. All methods 
must be evaluated individually42p45. 
(+) Sulfobromophthalein (BSP). Produces a violet color in alkaline solution which 
contributes to absorbance or obscures endpoint in titrimetric methods. 
(+) Zinc. Unlikely to be present in significant concentrations in biological fluids. 
Addition of cyanide overcomes interference43144. 
CATECtIOLAMINES 
A. In the screening method of Hingerty46, epinephrine and norepinephrine in 
urine are adsorbed on aluminum oxide at pH 8.4, eluted with dilute acid and oxidized 
with ferricyanide at pH 6.5. Addition of strongly alkaline ascorbate effects ring closure 
with formation of adrenochromes which produce a green fluorescence. In quantitative 
procedures, internal standards and sample blanks are included47. 
(+) B-complex vitaminsl. Large doses, especially of riboflavin, can produce similar 
fluorescence. 
(+) Erythromycin*8. Produces fluorescence in Hingerty’s method. 
(-) Formaldehyde4a. Inhibits fluorescence of added recovery standard in methods 
based on condensation of catecholamines with ethylenediamine. 
(+) Isoproterenolso. Inhaled as a bronchodilator. Metabolite produces false positives. 
(+) LevodopasO. Produces fluorescence similar to norepinephrine. 
(-) Methenamine mandelate (Mandelamine)@. This and other drugs containingmeth- 
enamine release formaldehyde which inhibits fluorescence (see above). 
(+) Methyldopa 51. This drug, itself a catecholamine, is the most common cause of 
false positive tests for catecholamines. 
(+) Quinidine, quinines3. Metabolites produce fluorescence. 
(+) Salicylatesl. Produce interfering fluorescence. 
(+) Tetracyclines48. Produce interfering fluorescence. Crout47 lists a number of drugs 
which do not affect urinary catecholamine determinations by his procedure. 
B. Metanephrines (methoxycatecholamines) are determined according to 
Pisano53 by acid hydrolysis, adsorption on Amberlite resin, elution, conversion to 
vanillin with periodate, and measurement at 360 nm. 
(+) Chlorpromazine54. The drug and its metabolites cause a false elevation, 
(+) Imipramine 54. Preliminary observations suggest interference. 
(-) Methylglucamine55. Present in certain radiopaque dyes (Renovist, Renografin) 
and consumes periodate, preventing oxidation of metanephrines to vanillin. 
CHLORIDE 
A. Titration with mercuric nitrate to form nonionized mercuric chloride. Di- 
phenylcarbazone indicator is used to detect the endpoint. 
B. Coulometvic-amperoretric titration by generation of silver ions. 
(+) Bromide. This ion reacts similarly to chloride in the above methods. In bromide 
poisoning, however, the bromide tends to replace chloride and the sum of the 
two halogens gives an apparent normal value for chloride56. 
C. Methods based on halide displacement o>f mercury from mercuric thiocyanate 
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with resultant formation of ferric thiocyanate. Absorbance measurements are made 
on the red-colored complex at 480 nm (manual or automated methods). 
(+) Bromide. Equimolar quantities of bromide yield more ferric thiocyanate in the 
reaction than does chloride. Thus, in the presence of bromide, this method yields 
higher results than the preceding methods56y57. 
CHOLESTEROL 
Cholesterol methodology has been reviewed recently by Tonks58 and Martinek59. 
A. Methods based on the Liebewnann-Burchard reaction (acetic anhydridesul- 
furic acid) applied directly to serum@‘. A green color is produced. 
(+) Bilirubin. C onverted to green pigment, biliverdin, in the reaction mixture. One 
mg of bilirubin is reported to produce color equivalent to as much as 20 mg of 
cholestero161. Interference is less in procedures involving preliminary extraction. 
The method of Abell et al.@, is generally recognized as a highly specific and satis- 
factory standard method for cholesterol determinations. 
B. Methods based on reaction with ferric ion in acetic acid-sulfuric acid mixture. 
A violet color is produced. The reaction may be applied directly to serum, as described 
by Zlatkis et aZ.63, or to protein-free extract+. 
(+) Aminopyrine (Pyramidon). Interference has been reported5*. 
(+) Bilirubin. Interference is less when protein precipitation or solvent extraction is 
usedG5. Various approaches have been used to eliminate bilirubinS9. 
(+) Bromide. Reportedly interferes when isopropanol extracts are used but not with 
ethanol extracts@. With isopropanol extracts, aserum bromide level of rommole/ 
liter increased the apparent serum cholesterol by 30 mg/dl. Preliminary precipita- 
tion of bromide with silver ion has been suggestedG7. 
(+) Chlorpromazine. Fifty pg in the final reaction mixture produced a red color with 
absorbance of 0.23 68. No interference was encountered in a proposed fluorometric 
method. 
(-) Nitrates and nitrites. These inhibit color development and the effect is the same 
per mole. Rice 69 has shown that IO pg of nitrate or nitrite in the final reaction 
mixture reduced the apparent cholesterol level by approximately 30%. Nitrate 
may be present in sulfuric acid. We have encountered nitrite in one lot of iso- 
propanol sufficient to depress the absorbance on a zoo mg/dl standard by 25%. 
(+) Salicylates. Interference has been suggested58. We have added salicylate to serum 
to produce levels of IOO mg/dl and have found no interference when the iron 
reaction is applied to isopropanol extracts. 
(-) Thiouracil. When used as a preservative at levels of 13 mg/dl, the apparent serum 
cholesterol was decreased by 30-40 mg/dlYO. 
(+) Tryptophan. Present in protein and produces a red color in the direct reaction 
when glyoxylic acid is present as a contaminant in acetic acid71. HenryT2 states 
that the top normal level of tryptophan in serum is about 3 mg/dl. In his method, 
I mg of tryptophan gave color equivalent to I mg of cholesterol. W7e have tested 
glacial acetic acid, containing IO g/liter of added glyoxylic acid, and have ob- 
served a decrease in apparent serum cholesterol values of approximately 40% 
when the iron-sulfuric acid reaction was applied either directly to serum or to 
isopropanol extracts. Addition of IO mg/dl of tryptophan to serum produced no 
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detectable increase in the apparent cholesterol levels with either technique. In 
general, however, direct determinations on serum by the iron-sulfuric acid meth- 
od gave higher results than when applied to extracts. This is probably a result 
of slight charring of protein during color development. 
(+) Vitamin A. Levels of 150 pg/dl in serum have been reported to increase the ap- 
parent cholesterol level by 100-150 mg/dl when the direct method is employed73. 
Subsequent reports have failed to confirm these findings~4. 
CORTISOL, PLASMA 
Cortisol is extracted into dichloromethane, washed with alkali, and mixed with 
ethanol-sulfuric acid. Fluorescence is measured after IO min. 
(+) Benzyl alcoho175. Some heparin solutions contain benzyl alcohol as preservative 
which reacts with an impurity in dichloromethane to produce a similar fluores- 
cence. Interference is significant at IO min and increases markedly by 20 min. 
The dichloromethane should be spectral grade, or redistilled over concentrated 
sulfuric acid to eliminate interferenceT6. 
(+) Spironolactone 77. Fluorescence emission spectrum is identical to that of cortisol. 
CREATININE 
Creatinine reacts with picrate in alkaline solution to form a reddish-brown I : I 
adduct (Jaffe reaction). Complete color development requires 15-20 min at 25’. 
Kinetic methods have appeared based on the rate of color developmenV8. At elevated 
temperatures, picrate is reduced to reddish-brown picramate by glucose and other re- 
ducing substances. Efforts to improve specificity of the reaction have included ether 
extraction and/or preliminary treatment with iodine to remove interfering substances 
(ref. 79). Adsorption of creatinine on Fuller’s earth or ion exchange resin has also been 
employed. Practically, the Jaffe reaction is usually applied directly to urine or protein- 
free filtrates without preliminary treatment of specimens. A recent study, applied to 
urine, indicates that the original Jaffe reaction is the most specific of several procedures 
investigatedsO. We have evaluated some reported interfering substances by adding 
alkaline picrate to pure solutions, both in the presence and absence of creatinine. 
Reaction conditions in our studies were essentially those of Bonsnes and Taussky*l 
with color development for 15 min at 25”. 
(+) Acetoacetic acid. Reaction with picrate occurs almost immediatelyT8. We find 
that IOO mg/dl of acetoacetic acid produces color equivalent to 3.4 mg/dl of 
creatinine. Color development was complete by I min. 
(+) Acetone 82. We find that 500 mg/dl of acetone produces color equivalent to 1.4 
mg/dl of creatinine. 
(+) Aminohippurates3. Produces a positive Jaffe reaction but does not interfere at 
the concentrations obtained during renal studies. 
(+) Ascorbic acid*&. Color development is ascribed to a reducing action. We find that 
250 mg/dl of ascorbic acid produces color equivalent to 1.9 mg/dl of creatinine. 
This concentration could occur in urine but the interference is negligible. 
(+) Fructoses5. We find that IOOO mgjdl of fructose produces color equivalent to 
1.0 mg/dl of creatinine after 15 min color development. Extension of incubation 
time results in marked increase in interference. 
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(+) G1ucoses2~80. Reaction appears negligible at 25”. We find that IOOO ml/d1 of glucose 
produces color equivalent to only 0.2 mgjdl of creatinine. 
(+) ~~thyldopa. Autolridation in alkaline solution produces a brown color. We find 
that IO mgjdl of methyldopa produces color equivalent to 1.0 mg/dl of creatinine. 
(+) Nitrofuran derivatives I. These produce a deep orange-brown color in urine 
specimens. 
(+) Phenolsulfonphthalein (PSI’). Color is produced in alkaline so1ution7s~87. Treat- 
ment with zinc in acid solution has been proposed to reduce BSP and PSP to 
leuco dyes which do not interfere. A separate alkalinized sample blank should 
also be satisfactory. 
(+) Protein 89~88. We find that 5 g/d1 of crystalline human serum albumin produces 
color equivalent to 2.2 mg/dl of creatinine. 
(+) Pyruvate. Produces a positive Jaffe reaction. One mg of pyruvic acid is reported 
to produce color only slightly less than I mg of creatininess*90. We find that IO 
mgldl of pyruvic acid produces color equivalent to 0.3 mgidl of creatinine. 
(+) Sulfobromophthalein (BSP)7s. Color is produced in alkaline solution. See under 
phenolsulfonphthalein. 
(0) Tausskysr lists a number of compounds that did not interfere when added to 
protein-free filtrates of serum, followed by treatment with iodine and ether ex- 
traction. 
ESTROGENS 
A. The followiytg com$omds weve found to interfere in a procedure described by 
Brown”2, based on fractionation of urinary estrogens and color development with a 
modified Kober reaction. An additional purification step was included in a subsequent 
modification that eliminated interference from all those listed93. 
(-) Cascara. Decreased values for estradiol. 
(-) Cortisone. Decreased values for estradiol. 
(+) Meprobamate. Increased values for estriol. 
(+) Phenolphthalein. Increased values for estradiol. 
(-) Senna. Decreased values for estrone. 
(-) Stilbestrol. Decreased values for e&radio1 and estriol. 
B. Methods fop determination of estviol in pregnancy w&e commonly involve 
preliminary acid hydrolysis to release the free steroid. 
(-) Hydrochlorothiazide. Destroys estriol during acid hydrolysi9. 
GLUCOSE 
A. Glucose oxidase-$eroxidase (GO--POD) unethods. 
Glucose+ 0, &‘+ gluconic acid-+- H,O, 
H,O, + chromogen POD oxidized chromogen (color) 
The first reaction is highly specific for glucose and has been adapted for use 
with PO, electrodes. The second reaction is less specific; reducing substances either 
compete with the chromogen for H,Oz, or keep the chromogen in the reduced state, 
leading to low results. Somogyi filtrates are recommended to eliminate or minimize 
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interferences with determinations on serum. Most major interferences have been ob- 
served with paper strip tests applied to urine. 
(-) Ascorbic acid. Competes with chromogenQ5. 
(-) Bilirubin. Competes with chromogen. 
(-) Bilirubin glucuronide. Inhibits reactionQ6. 
(-) Formaldehyde. Inhibits reaction. May be added to urine as a preservative. 
(-) Glutathione. Competes with chromogen. Not present in serum or Somogyi filtrates 
of whole blood. 
(-) Homogentisic acid. Acts as a reducing substanceD6. 
(+) Hypochlorite. Direct oxidation of chromogen. May be present as a contaminant 
from bleaches, denture cleansers, etc.Q7. 
(-) Levodopa. A metabolite, 3,4_dihydroxyphenylacetic acid (DOPAC), acts as a 
reducing substance98*9Q. 
(+) Oxazepam. Reported to act as a Cu(II)-reducing agent and to produce false 
elevations in a method in which total reducing substances were measured before 
and after treatment with glucose oxidase loo. These in vitro findings require further 
study to rule out possible effects of other ingredients in the capsules. 
(-) Phenazopyridine (Pyridium). Reaction is delayedQ. 
(-) Tetracyclines. Parenteral preparations may contain large amounts of ascorbic 
acid which interfere+. 
(-) Uric acid. Competes with chromogen. 
B. o-To&dine reacts with glucose in hot acetic acid solution to produce a green 
color. The reaction is reasonably specific for glucose in serumlo and in the average 
urine specimenlo3. 
(+) Dextran. Turbidity is produced in acetic acid so1ution10a~105. 
(+) Disaccharides. Maltose and lactose produce 5 and 33 O!, as much color, respective- 
ly, as glucose lo2 We have also observed some color production with sucrose, .
possibly as a result of acid hydrolysis to monosaccharides. 
(-) Formaldehyde. Produces an abnormal orange color and reduces the intensity of 
the green color usually produced by glucose in the o-toluidine reaction. 
(+) Hexoses. Galactose and mannose produce color equivalent to glucose. Fructose 
does not reactlo2. 
(+) Pentoses. These produce an orange color with the reagent. The reaction has been 
applied to measure xylose in urine. 
C. Ferricyanzide is reduced by glucose in hot alkaline solution to colorless ferro- 
cyanide. The method is reasonably reliable when applied to dialysates of nonuremic 
serum, but is unsatisfactory for measurements on urine. We have observed increases 
in apparent glucose values with the following when analyzed in pure solutions. 
(+) Creatinine. I mg is equivalent to 1 mg glucose. 
(+) Uric acid. I mg is equivalent to 0.5 mg glucose. 
D. Copper-reductiolz methods. Numerous modifications have been proposed. For 
whole blood glucose, a Somogyi filtrate provides greatest specificity. For serum glucose, 
a Folin+Wu filtrate is about equally satisfactory. Uric acid has been shown to 
produce color equivalent to 75% of glucose by the Folin-Wu method but no color 
with the Nelson-Somogyi method. Glucuronic acid, however, appears in substantial 
amounts in either filtratelo’. 
The following interferences refer almost entirely to the measurement of total 
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reducing substances in urine, either with Benedict’s reagent or Clinitest tablets (Ames 
Co.). Such determinations are done primarily as semiquantitative tests for glucose in 
urine but are also helpful to detect pentosuria, lactosuria, etc., where glucose oxidase 
strips would be negative. Concentrations of reagents are adjusted to produce “nega- 
tive” or trace reactions for reducing substances, such as creatinine and uric acid, 
normally present in urine. 
(+) Aminopyrine. Glucuronide metabolitelo’. 
(&) Amino acids. Variable interference with high concentrations. Effect in urine 
specimens is probably negligible~05,~09. 
(+.) $-Aminosalicylate. Probably excreted as a metabolite, similar to gentisic acidllo. 
(+) Ascorbic acid. Positive test with concentrations of 50 mg/dlgj. 
(+) Cephalothin (Keflin) . Produces a blackish-brown color with Clinitest tablets. 
(-I_) Chloral hydrate. A metabolite, trichloroethanol, is excreted as the glucuronide. 
(+) Chloramphenicol (Chloromycetin)lll. 





(+) Glucuronide metabolites. Present in blood or urine and act as reducing agentslla. 
(+) Homogentisic acidllo. 
(+) Indican115. 
(+) Isoniazidllo. 
(+) Levodopa. A major metabolite, DOPAC, is a reducing agenWg9. 
(+) Metaxalonel”. 
(+) Nalidixic acid. Appears as glucuronide in both blood and urinelIe. 
(+) Neocinchophen (Tolysin) l12. 
(+) Nitrofuran derivatives. Metabolites act as reducing agents?. 
(+) Oxazepam. Reported to reduce Cu(I1) in Somogyi methodloo. 
(+) Oxytetracycline (Terramycin)lll. 
(+) Penicillin. Drug and degradation products, in high concentrations, act as re- 
ducing agents110+7. 
(+) Probenecid15. 
(+) Radiographic contrast media. Urine may produce a greenish-black reaction 
z--20 h after administration of sodium diatrizoate (Hypaque)ll*. The drug alone 
does not react unless uric acid or creatine is present. 
(+) Reducing sugars (other than glucose). These include fructose, galactose, lactose, 
maltose, rhamnose, ribose, and xylose110T113. 
(+) Saccharoids. In whole blood these reducing substances are principally glutathione 
and ergothioneine. Increased glucuronic acid is reported in the blood of diabetics 
(ref. 119). 
(+) Salicylates. A metabolite, gentisic acid, is a reducing agentlIz. 
(+) Streptomycin. Drug and metabolites are reducing agentslZO. 
(-) Sulfanilamide. Forms a colorless, soluble Cu(I1) complexlZ1. 
(+) Sulfathiazole. Forms a yellow to orange complex in alkaline urine121. 
(+) Vaginal powders. May contain glucosel. 
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HOMOVANILLIC ACID 
~omovan~ic acid in urine is isolated by c~~romatography, then oxidized and 
converted to a fluorescent derivative. 
(+) Salicylatel22. Interfering fluorescence is caused by acetylsalicylic acid, salicylic 
acid and an unidentified metabolite. Blank readings are increased 50-100 fold. 
IT-HYDROXYCORTICOSTEROIDS 
This group of steroids (IT-OH) is commonly determined by the Porter-Silber 
reaction123~124. Following enzymatic hydrolysis with ,%glucuronidase, the free steroids 
are extracted into chloroform, washed with dilute alkali, then re-extracted into a 
strongly acid solution of phenylhydrazine. The absorbance of the yellow derivative is 
measured at 410 nm. (r7-Ketogenic steroids are discussed under r7-ketosteroids. See 
also cortisol, plasma). 
The most extensive single study on drug interference in steroid dete~nations 
is that of Borushek and Gold14. Determinations were made in V&O on solutions of 23 
drugs, both alone and in the presence of standards, and on 24-h urine collections from 
patients before and after receiving the medications. Observations reported include 
absorbance produced by the drug alone, increased or decreased absorbance of standard 
in the presence of the drug, and apparent increase or decrease in urinary steroid ex- 
cretion following a~injstration of the drug. Only drugs showing the latter effect are 
included below. 
(+) Acetone. Reported to interferelz5. 
(+) Chlordiazepoxide (Librium)14. 
(-) Chlorpromazine (Thorazine)l*Ja6. 
( +) ColchicineB’. 
(+) Chloral hydratelas. Produces color in the Porter-Silber reaction with butanol as 
extractant but not with chloroformlz7. 
(+) Etryptamine (Monase)l*. 
(+) Hydroxyzine (Atarax) 14. A brownish-yellow color is produced. 
(+) Meprobamate (Equanil)l*. 
(+) Methenamine mandelate (~~andela~ne~ rzg. Produces fo~aldehyde which causes 
an apparent increase in value unless the Allen correction as applied to absorbance 
readings. 
(+) Paraldehydela791z*. 
(+) Penicillin G. Produces a similar coIor reactionl. 
(-) Pentazocine (Talwin)13. Administration of IOO mg/day decreased apparent 17- 
OH excretion approximately 16%. This may be a pha~acologic effect. 
(+) Potassium iodide128. Excreted in urine and produces a yellow color in the Porter- 
Silber reaction with butanol as extractant but not with chloroforml”7, 
(-) Prochlorperazine (Compazine) lZ6. An abnormal yellow-orange to pink color ap- 
pears in both the urine blank and test solutions. Subtraction of the blank does 
not provide adequate correction. 
(-) Prometh~ine (Phenergan) lZ6. Effect is similar to prochlorperazine. 
( -) Propoxyphene (Darvon) 13. Administration of 195 mglday decreased apparent 
XT-OH excretion by 18%. This may be a pharmacologic effect since the drug had 
no effect in vitro. 
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(+) Quininelz7. 
(-) Reserpine (Serpasil)14. This may be a pharmacologic effect since the drug produces 
an orange-red color in the final reaction mixture and contributes to absorbance. 
(-) Salicylates Iso Following large doses, salicylate glucuronide in urine acts as a .
competing substrate for glucuronidase. Complete hydrolysis of conjugated ste- 
roids requires more enzyme and prolonged incubation times. 
(+) Spironolactone (Aldactone) 13r. The drug or its metabolite produces a similar color 
reaction. 
(+) Triacetyloleandomycin133. Administration of I or 2 g/day increased apparent 
17-OH excretion by 2 to 4-fold. Addition of 0.25 g to a 24-h urine specimen 
elevated the apparent value from 2.9 to 10.5 mg. 
5-HYDROXYINDOLEACETIC ACID (5-HIAA) 
A. Screening test on urine. A purple color is developed by reaction with I- 
nitroso-z-naphthol and nitrous acid la3. This reaction is said to be specific for 5-hy- 
droxyindoles. Extensive work by Mustala 134 however, has defined the chemical con- , 
figuration necessary for color development in the reaction134. 
(+) Acetanilide 133. A metabolite, $-hydroxyacetanilide, produces similar color. This 
drug is little used at present. 
(+) B ananas135. Ingestion of 3 bananas per day doubled the normal excretion of 
5-HIAA. Apparently this is a true increase in excretion. 
(-) Formaldehyde. Released from various drugs. Inhibits color development136. 
(+) Glyceryl guaiacolate (Robitussin)134p137. 
(-) Keto acids13*. Excessive amounts interfere with color formation. 
(+) Mephenesin and mephenesin carbamate 13s. Metabolite reacts to produce color. 
(-) Methenamine mandelate 136. Releases formaldehyde. See above. 
(+) Methocarbamol 139. Metabolite reacts to produce color. 
(+) Phenacetin. Produces the same metabolite as acetanilide. 
(-) Phenothiazines 140. Compounds inhibit color development. 
B. Qua&tat&e tests. Urine is treated with dinitrophenylhydrazine to remove 
keto acids. 5-HIAA is extracted, purified, and reacted with the same reagents as in 
the screening test. By the method of Udenfriend et a1.13*, metabolites of mephenesin, 
methocarbamol and glyceryl guaiacolate produce falsely elevated results. By per- 
mitting the final solution to stand to allow fading of some interfering colors, and by 
reading absorbance at two wavelengths, Mustala claims to have eliminated or detected 
interference from these compounds134~141. 
IODINE UPTAKE, RADIOACTIVE (See thyroid function tests.) 
KETONE BODIES (URINE) 
This category includes qualitative tests for acetone and acetoacetic acid (dia- 
cetic acid), and for phenylpyruvic acid. 
A. Gerhardt test. Ferric chloride reacts with acetoacetic acid to produce a red 
color. Concentrations greater than 25-50 mg/dl give a positive test. 
(+) Phenothiazines. Metabolites form a pink or purple color with the reagent142. 
Cdin. Chim. Ada, 41 (1972) 395-434 
CHEMICAL INTERFERENCE BY DRUGS 409 
(+) Salicylate+3. Produce a red color. Interference from these and other drugs is 
detected by boiling acidified urine to destroy acetoacetic acid, then retesting. 
B. Nitroprtisside @us alkali. This reagent reacts principally with acetoacetic acid 
to form a purple color. A reagent tablet or test strip is commonly used (Acetest tablets 
or Ketostix, Ames Co.). The test is sensitive to approximately IO mg/dl of acetoacetic 
acid or IOO mg/dl of acetone 14*. Salicylates do not interfereIda. 
(+) Levodopa and methyldopa. Produce color with the reagent145pL46. 
(+) Paraldehyde. Acetaldehyde produces color with the reagent14’. 
(-) Phenazopyridine (Pyridium). Slightly positive reactions are masked by the color 
of the drugg. 
(+) Phenolsulfonphthalein (PSP). Reddish-purple color with alkali. 
(+) Phenylpyruvic acid (large quantities). Present in urine from patients with phenyl- 
ketonuria. 
(+) Sulfobromophthalein (BSP). Partially excreted in the urine and produces a 
purple color with alkali. 
C. A screening test for phenylketonuria consists of adding a solution of ferric 
chloride to urine to produce a transient blue-green color with phenylpyruvic acid. 
(+) Levodopa148. Urine from patients receiving 1-5 g/day became a dark, muddy 
black-brown color upon addition of ferric chloride. 
(-&I) Phenothiazines142. Metabolites form a pink or purple color with the reagent 
which may mask true color of the test. 
(&) Salicylates I42 A red color is produced which may mask the true color of the test. .
I$‘-KETOSTEROIDS AND IT-KETOGENIC STEROIDS 
r7-Ketosteroids (17-KS) are commonly measured by some modification of the 
Zimmerman reaction. Following acid hydrolysis, the free steroids are extracted into 
a nonpolar solvent and washed with alkali. A portion of the extract is evaporated and 
the steroids reacted with m-dinitrobenzene in alcoholic alkaline solution. The ab- 
sorbance, after development of the red-purple color, is measured at 520 nm. 3-Keto- 
steroids and zo-ketosteroids also react but produce less color than 17-KS. 
r7-Ketogenic steroids (17-KGS) include the r7-hydroxycorticosteroids (dis- 
cussed separately) as well as certain other steroids, such as pregnanetriol, with a 17- 
hydroxy, zo,zI-side chain. These compounds may be oxidized to 17-KS by treatment 
with sodium bismuthate in acetic acid solution, then measured by the usual Zimmer- 
man reaction. Pre-existing 17-KS are determined separately and subtracted from the 
total to provide a measure of r7-KGS. In subsequent modifications, pre-existing 17- 
KS are eliminated by reduction with borohydride prior to bismuthate oxidationl49. 
Metaperiodate may be substituted for bismuthate as an oxidizing agent. 
The following refer mainly to interferences encountered in actual urine speci- 
mens, rather than to reactions with pure drugs. 
(+) Acetone 150. Produces a brown color in the Zimmerman reaction. 
(-) Chlordiazepoxide (Librium)la. Apparent decrease in 17-KS excretion. This may 
be a pharmacologic effect since the pure drug forms a pink color in the reaction 
and contributes to the absorbance. 
(&) Chlorothiazide (Diuril)151. Reported to interfere but not confirmed by in vivo 
studie+. 
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(+) gupromazine (Thorazine) 14. Produces a red color in the Zimmerman reac- 
(+) Cloxacillin152. Produces a purple color in the Zlmme~an reaction. 
(3) Dextroamphetamine (Dexedrine) l&l. Reported to interfere but not confirmed by 
in ZU’IIO studies?“. 
(+) Ethinamate (Valmid) 14. Produces a deep red color in the Zimmerman reaction. 
(+) lZEp;amine (Monase) 14. Slight increase in 17-KS values reported with i-rz viva 
’ (-) Gl ucoselsZ. In the r7-KGS methods, excess glucose acts as a reducing agent to 
consume bismuthate or metaperiodate, resulting in possible incomplete oxidation 
of the steroid side chain. Glucose can be eliminated by yeast fermentation, by 
increasing the concentration of oxidant, or by preliminary extraction of the 
steroids with ether-ethanol (3 : I). The latter approach is most reliable’“s. 
(&) ~~~~s~~rnide (D ori en lJ1. Reported to interfere but not confirmed by i?z vkvo d ) 
(+) Meprobamate (Equanil) 153,154. Produces a yellow col.or in the Zimmerman reaction. 
Absorbance corrections, based on readings at 2 or 3 wavelengths, all yield false 
low results. 
(-) Metyrapone (Metopirone) 152. In rare cases a metabolite appears to compete with 
17-KS for ~~-dinitr~)benzene. 
(+) Nalidixic acid Is5 Produces an orange color in the Zimmerman reaction. A similar _ 
reaction was demonstrated in vitro. 
(+) Paraldehyde151. Reported to interfere. 
(+) Penicillin G156. Drug is excreted largely unchanged and behaves as a ketogenic 
chromogen. Apparent 17-KS and 17-KGS excretion are both increased but the 
latter is more striking. 
(+) Phenaglycodo1157. The drug itself does not give the Zimmerman reaction but 
during acid hydrolysis of conjugated 17-KS the drug undergoes a pinacol re- 
arrangement to form a ketone which does react. 
(&) Phenazopyridine (Pyridium) 151. Reported to interfere but not confirmed by in 
vivo studies14. 
(+) Prochlo~erazine (Compazine) 15%. Reported to interfere but not con6rmed by 
ilz v&o studie+. 
(-) Propoxyphene (Darvon) 13. Administration of 195 mglday decreased apparent 
17-KS excretion by zg%. This may be a pharmacologic effect since the drug had 
no effect i?z -i&o. 
(+) Quinine 151. Reported to interfere. 
(-) Radio~aphic contrast media 15%. Studies were made with meglumine iodipamide 
(Duografin) and meglumine iothalamate (Conray). Mean x7-KGS values fell from 
9.3 to 3.5 mg/day after administration. The compounds act as reducing agents, 
similar to glucose. Preliminary extraction of urine with ether-alcohol eliminated 
the interference. 
(-) Reserpine (Serpasil) 14. Apparent slight decrease in 17-KS excretion. This may 
be a pharmacoIo~c effect. The final reaction mixture has an orange color and 
should contribute to absorbance. 
(+) Spironolactone (Aldactone) x31. Produces a similar color reaction. 
(+) Triacetyloleandomycin. 132. A false increase in 17-KS values was observed in pa- 
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tients receiving I-Z g/day. Addition of 0.25 g to a 24-h urine specimen elevated 
the apparent 17-KS value from 9.7 to 18.0 mg. 
(+) Urinary chromogens. Various naturally occurring pigments are extracted and 
produce color in the Zimmerman reaction. This interference can be effectively 
eliminated by adding formaldehyde to urine prior to acid hydrolysis159. 
LACTIC DEHYDROGENASE 
This enzyme catalyzes the reaction : 
Lactate+NAD+- + Pyruvate+NADH+H+ 
Calorimetric assays using the pyruvate-to-lactate reaction and measuring the dis- 
appearance of pyruvate with the dinitrophenylhydrazine reaction will give low results 
if NADH is omitted from standard solutions of pyruvate. Pyridine nucleotides react 
with the reagent to yield a product which absorbs maximally at the same wavelength 
as pyruvate. The nucleotide competes for the color reagent with increasing effective- 
ness as the pyruvate concentration decreases during the reaction16°. 
LIPASE 
In the turbidimetric method of Vogel and ZievelG1, serum lipase activity is 
related to the decrease in absorbance observed during incubation of an olive oil emul- 
sion. 
(+) Bilirubin lfi2. Apparent lipase activity was shown to be elevated in proportion to 
the concentration of bilirubin. A titrimetric method was not affected. The inter- 
fering substance, presumably bilirubin, can be removed with DEAE cellulose. 
MAGNESIUM 
Magnesium reacts with Titan Yellow in alkaline solution to produce a pink 
complex which is measured spectrophotometrically. 
(-) G1uconate163. Administration as the calcium salt resulted in falsely low results by 
the Titan Yellow procedure but not in methods involving phosphate precipita- 
tion or preliminary ashing. The effect was confirmed in vitro. 
METANEPHRINES (See catecholamines.) 
PHOSPHATASE, ALKALINE 
(+) Albumin infusions 164,165. Albumin prepared from human placentas contains heat- 
stable alkaline phosphatase. In one case, the serum alkaline phosphatase rose to 
160 Bodansky units after multiple infusions and remained elevated for IO days 
following cessation of therapy ls4. Manufacturers vary in whether or not they use 
only venous blood as a source of albumin lG6. The heat-stable enzyme may be 
detected by incubating serum at 60” for I h to destroy alkaline phosphatase of 
non-placental origin. 
(-) Albumin infusions. In contrast to the above, albumin prepared from venous 
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blood appears to inhibit serum alkaline phosphatasel67. The effect could be dem- 
onstrated in vitro with more than one method of assay. Addition of magnesium 
partially reversed the inhibition. 
(+) Sulfobromophthalein (BSP). This dye could interfere in methods based on final 
color development in alkaline solutions, depending on the wavelength used to 
measure absorbancel@. 
PHOSPHATE, INORGANIC 
Inorganic phosphate, in a protein-free filtrate of serum, reacts with molybdate 
to form phosphomolybdate which, in turn, is reduced to a molybdenum blue complex 
by aminonaphtholsulfonic acid or other suitable reducing agents. The following com- 
pounds, if present, complex with molybdate and prevent full color development169. 
(-) Citrate. 
(-) Mannitol. The compound has been used to promote diuresis. Levels reached in 




A screening test for urinary coproporphyrins is performed by adding acetic 
acid to urine and extracting with ether. Coproporphyrins in the ether layer are detect- 
ed by their pink fluorescence in ultraviolet light. 
(+) Phenazopyridine (Pyridium). Colors the urine orange-brown and is often mis- 
taken for porphyrins. The interference is eliminated by adding a small amount 
of sodium dithionite (Na,S,O,) to the urine prior to extractiona. 
(+) Tetracyclinel’l. A pink fluorescence is observed when both tetracycline and 
phenazopyridine are present together. Neither drug alone was found to interfere 
in the screening test. 
PREGNANCY TESTS 
These tests depend on the measurement of human chorionic gonadotropin 
(HCG) in urine in early pregnancy. Biologic pregnancy tests employ animals, such as 
frogs, rats, and rabbits. More recently, immunologic tests utilizing latex particles or 
erythrocytes, coated with HCG, and an antiserum to HCG have been developed. 
When these are mixed together, agglutination occurs. When HCG in the urine of a 
pregnant woman is added to the system the antiserum (anti-HCG) is neutralized and 
agglutination does not occur, Thus, agglutination-inhibition is interpreted as a positive 
test. Various commercial reagent kits and modifications are available. 
(+) Phenothiazines. False positive frog tests were reported in 8 of rg patients re- 
ceiving promazine (Sparine) and in 5 of II patients receiving chlorpromazine 
(Thorazine). Use of serum, rather than urine, was recommendedlT2. One report 
describes a false positive immunologic test on urine from a patient receiving 
chlorpromazinel73. The test became negative z. weeks after the drug was with- 
drawn. At the time of the positive test, however, the patient also showed+ pro- 
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teinuria which could be responsible for the false positive. In subsequent reports, 
false positive immunologic tests were attributed to phenothiazines for some 
reagent kitslT4; other investigators were unable to demonstrate either false posi- 
tive or false negative results associated with phenothiazine medication17s. Re- 
lease of luteinizing hormone (LH) or interstitial cell stimulating hormone (ICSH), 
following phenothiazine therapy, has been suggested as a possible mechanism for 
false positive pregnancy tests 176t177. Both hormones cross-react with anti-HCG. 
(+) Protein. A number of reports described false positive immunologic tests for 
pregnancy attributed to protein in urine 178-180. Presumably these were caused 
by contamination of commercial HCG preparations with other antigenic pro- 
teinslsl. 
PROTEIN (SERUM) 
A. B&ret Yea&o%. A violet color is produced with alkaline--Cu(II)-tartrate 
reagent. Absorbance is measured near 550 nm. 
(+) Bilirubin. Effect is negligible except in extreme jaundice. We have observed that 
a bilirubin level of 20 mg/dl increases the apparent total protein by approximately 
0.1 g/dl. 
(+) Dextran. Produces a fine turbidity with Cu(I1); hence, a separate serum blank 
correction is inadequateZz. Solutions should be observed for a Tyndall effect. 
Ethylene glycol may be incorporated in biuret reagent to eliminate interferencelss. 
(+) Hemoglobin. Reacts with biuret reagent but also contributes directly to absorb- 
ance. The color produced in the biuret reaction by I mg of hemoglobin is equiva- 
lent to 1.9 mg of serum proteinls3. 
(+) Lipemia. Various blank corrections have been proposed. The most satisfactory 
approach seems to be ether extractionls4. 
(+) Phenazopyridine (Pyridium) . Orange-brown color contributes to absorbanceg. 
(+) Sulfobromophthalein (BSP). Similar color is produced in alkaline solution. We 
have observed that a plasma level of 2 mg/dl (corresponding to 20% retention of 
BSP) increases the apparent total protein by 0.3 g/dl. 
B. Dye biding procedures fog albunk. For example, 2-(4’-hydroxyazobenzene) 
benzoic acid (HABA) produces color with albumin in buffer solution at pH 5. Ab- 
sorbance is measured at 505 nm. 
(-) Bilirubin. Competes with HABA for binding sites on albuminls5. Effect is offset 
to some extent since bilirubin also has significant absorbance at 505 nm. The 
latter effect is eliminated with bromcresol green methods where absorbance is 
measured at 600 nmls6. 
(+) Heparin. Presumably promotes binding of dye to globulinsls7. Thus, a series of 
corresponding sera and heparinized plasma showed mean values of 4.2 and 9.1 
g/d1 respectively. We have not been able to demonstrate such interference with 
the dye SpecTru AB2 (Pierce Chemical Co., Rockford, Ill.). 
(-) Penicillin. Presumably competes with HABA for binding sites on albuminlss. 
Interference is usually negligible. 
(+) Phenazopyridine (Pyridium). Contributes to absorbance. Serum blanks are re- 
quired in the HABA procedure. 
(-) Salicylate. Competes with HABA for binding sites on albuminls5~ls7. Two hours 
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following ingestion of 4 aspirin tablets (1.3 g), the apparent serum albumin level 
was reported to decrease by 14%. 
(-) Sulfonamides. The mechanism is similar to that of salicylatelss. 
C. Electvophoresis of semin proteins. 
(&) Iodinated radiographic contrast media. At serum levels expected during diag- 
nostic studies, the peaks due to albumin and to cc- and P-globulins flatten or dis- 
appear. A high peak appears in the y-globulin region18*. 
(A) Penicillin. High doses, given intravenously, are reported to cause formation of 
bis-albunmilss. The penicillin-albumin complex has greater electrophoretic mo- 
bility than normal albumin. 
PROTEIN (CEREBROSPINAL FLUID) 
A. Twbidimetric methods based on addition of sulfosalicylic acid or trichloro- 
acetic acid. Henry et al. have reported that albumin produces 2.4 times as much 
turbidity as globulin with sulfosalicylic acid reagent lge. With trichloroacetic acid, 
globulin produces about 20% greater turbidity than albumin. A mixed reagent was 
recommended. Pennock et al.lsl recommend a mixture of sulfosalicylic acid and 
sodium sulfate with which the turbidity produced is independent of the relative con- 
centrations of albumin and globulin. 
(+) Bilirubin. Absorbance due to bilirubin is especially significant near 460 nm. This 
can be minimized, but with some loss in sensitivity for turbidimetric measure- 
ments, by using wavelengths above 500 nm. In addition, a sample blank should 
be included for xanthochromic fluids. 
B. Methods based on the use of alkaline-Cu(II)-tartrate and Folin-Ciocalteu 
reaged (phosphotungstic-phosphomolybdic acid). A blue color is produced. The Folin- 
Ciocalteu reagent alone reacts with phenols in general and considerable drug inter- 
ference can be expected. Results spuriously high by as much as 67 mg/dl have been 
reported. A deproteinized sample blank is recommendedlg2. The following substances 
have been reported to produce falsely elevated values, or color with the reagentlgz-194. 
Figures in parentheses show the apparent mg increase in protein per mg of substance 
tested. 
(+) p-Aminobenzoate (1.8) 
(+) p-Aminosalicylate (4.0) 
(+) Chloramphenicol (0.1) 
(+) Chlorpromazine (0.5) 
(+) Epinephrine (1.5) 
(+) 5-Hydroxyindoleacetic acid (3.2) 
(+) 5-Hydroxytryptophane (3.9) 
(+) Imipramine (Tofranil) (3.5) 
(+) Oxytetracycline (Terramycin) (2.4) 
(+) Penicillin (0.5) 
(+) Phenacetin (0.1) 
(+) Salicylate (2.3) 
(+) Serotonin (3.1) 
(+) Streptomycin (0.3) 
(+) Sulfonamides (0.3-0.6) 
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(+) DL-Thyronine (2.9) 
(+) Tyramine (2.7) 
(+) Tyrosine (3.3) 
PROTEIN (URINE) 
Quantitative methods are usually similar to the turbidimetric methods for 
cerebrospinal fluid. A suitable blank must be included to correct for absorbance by 
urinary pigments. The following observations pertain to qualitative tests for protein 
in urine. 
A. Precipitatiopz of protein with sulfosalicyclic acid or trichloroacetic acid, or by 
heating urine at pH 4 to 5. Certain drugs, metabolites, or diagnostic agents may pre- 
cipitate under these conditions. Of these methods, the heat test appears to be the 
most specific for protein. 
(+) P-Aminosalicylic acid105. 
(+) Cephalothin and cephaloridinelg6. 
(+ ) Iodinated radiographic contrast media1s7-201. 
(-j-) ~enic~lin111~117. 
( -+) Tolbutamide metabolit~~“~-~3. 
B. Indicnto~ tablets OY stri$s. These methods are based on the so-called protein 
error of indicators. The test reagent is bromphenol blue buffered to a pH of about 3. 
Color changes from yellow to blue in the presence of protein. These are available com- 
mercially as Albustix strips and Albutest tablets (Ames Co.). Sensitivity is about 
20-30 mg protein/d1 and the specificity appears better than with precipitation tech- 
niques. The strips are not affected by radiographic contrast media. 
(+) Alkaline urine. Urine must be highly buffered and strongly alkaline to overcome 
buffer action of the strips or tablets. Such interference is rarezol. 
PROTEIN-BOUND IODINE (See thyroid function tests.} 
PROTHROMBIN 
Plasma prothrombin activity is estimated by means of the prothrombin clotting 
time. In the one-stage method, developed by Quick, oxalated plasma is mixed with 
excess thromboplastin and a predetermined amount of calcium ion. The time for clot 
formation is measured and compared with that for a normal control. 
Alterations in clotting time associated with drug ad~nistration are not the 
result of test interferences, but rather arise from true changes in plasma levels of pro- 
thrombin, caused by interactions of other drugs with anticoagulants. The anticoa- 
gulants are carried in plasma bound to protein, mainly albumin, from which they can 
be displaced by competing drugs such as salicylates, phenylbutazone, oxyphen- 
butazone, indomethacin, and some sulfonamidesl. Increased amounts of active anti- 
coagulant are thus made available and the prothrombin time is increased. Conversely, 
withdrawal of such drugs in a patient stabilized on anticoagulant therapy releases 
binding sites, leading to subsequent decrease in available anticoagulant, and a de- 
crease in prothrombin time. 
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In addition, some drugs induce formation by the liver microsomes of enzymes 
which metabolize not only the drugs but other substrates. Barbiturates, for example, 
induce enzymes which metabolize coumarin, reducing its effect and decreasing pro- 
thrombin time. Sudden withdrawal of these drugs from patients stabilized on the drug 
and an anticoagulant may lead to a rapid and serious increase in prothrombin time, 
associated with a fall in prothrombin levels. These potentially serious interactions, 
which occur frequently but have often been unanticipated, are described thoroughly 
in recent reviews by Sigell and Flessa2*4 and by Koch-Weser and Sellers20”. 
1'9 TEST 
Phenolsulfonphthalein (PSP, phenol red) is injected intravenously. The amount 
excreted in the urine during a timed interval provides an index of kidney function. 
The urine is made alkaline to develop a reddish-violet color which is measured spectro- 
photometrically. 
(+) I&Dihydroxyanthraquinone (Danthron) 206. This peristaltic stimulant is a red dye 
which is absorbed and excreted in the urine to produce an apparent higher excre- 
tion of PSP. 
(+) Ethoxazene (Serenium). Colors the urine orange-red. 
(-) Penicillin~o?. Competes with PSP for excretion by the kidney. 
f + ) Phenazopyridine (I? yridium) s. Colors the urine orange-brown. Removed by 
butanol extraction after adding alkali. 
(-) Salicylates 207. Compete with PSP for excretion by the kidney. 
(+) Sulfobromophthalein (BSP). Excreted partly by the kidney and produces a color 
with alkali similar to PSP. The two tests should not be performed at the same 
time. 
(-) Sulfonamides 207. Compete with PSP for excretion by the kidney. 
SPECIFIC GRAVITY (URINE) 
(+) Radiographic contrast media 2os. We have observed urine specific gravities as 
high as 1.075 fo~o~v~g intravenous injection of diatrizoate (H~~aque). 
T, AND T, TESTS (See thyroid function tests.) 
THYMOL TURBIDITY 
A buffered solution of thymol is mixed with serum. Increased turbidity is ob- 
served with serum from patients with hepatocellular damage, especially those with 
infectious hepatitis. 
(-) Heparin. Thymol turbidity, measured on either plasma or serum, decreased from 
17 units to 3-5 units as heparin concentration was increased from zero to 0.5% 
(refs. 209, 210). Thus, the effect appears to be related to heparin, rather than to 
differences in plasma and serum. We have observed failure to develop adequate 
turbidity in oxalated plasmas when compared to corresponding serums. 
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THYROID FUNCTION TESTS” 
Methodology is discussed by Berger 211. The special problem of interference by 
iodine-containing substances has been reviewed by Rapport and Curtis212, and by 
Liewendah1213. In this section we have also included a number of pharmacologic effects 
since, in some cases, the exact mechanism of alteration of values is obscure. Either 
category of results could be misleading, when arriving at a diagnosis. 
A. Protein-bound iodine (PBI). Serum proteins are precipitated and washed to 
remove inorganic iodine. Sodium carbonate is added, to minimize loss of iodine in the 
ashing step, and the precipitate is incinerated to destroy organic matter and to convert 
thyroxine iodine to inorganic iodide, which is quantitated by its catalytic effect on the 
ceric-arsenite reactionz?4. The Technicon procedure for automated determination sub- 
stitutes digestion by a mixture of sulfuric, nitric, and perchloric acids for the alkaline 
ashing step. PBI procedures have been reviewed by Chaney*15. Davis21G, and recently 
AclandZ1’, have reviewed the factors affecting the PBI test. Major classes of drug 
interference include iodine-containing compounds and substances which affect the 
amount of thyroxine (T4) in transport. 
(0) Acetazolamide. No effect on test2r8. 
(-) p-Aminobenzoate. Antithyroid activity has been suggested219. 
(-) Aminoglutethimide. Competes for T, binding sitesl. 
(-) p-Aminosalicylate. Antithyroid activity has been suggestedzzo-222. 
(-) Androgens, anabolic steroids. These decrease the level of thyroxine-binding 
globulin (TBG), thus decrease total T42z3. 
(-) Barbiturates. Compete with T4 for TBPA sites2%225. 




Bromides. Some preparations contain iodide as a contaminantzZO. Three of 6 pa- 
tients given massive doses of potassium bromide-ammonium bromide showed 
elevated PBIZZ6. 
Busulfan. Normal PBI levels observed in z individuals following long-term 
administrationZZ7. 
Calcium. Calcium loading and subsequent withdrawal had no effect on test in 
7 subjectsz2*. 
(-) Chlorpromazine. Reports are conflicting. In one experiment, 5 patients given 
600 mg/day showed an average decrease in PBI of 1.6 pg/dl. Ten patients given 
chlorpromazine and other drugs showed significantly increased T, turnoverZZ9. 
Antithyroid activi.ty has been suggested230. 
(-) Chlorpropamide. Electrophoresis shows competition for TBG sitesZ31. 
(0) Chorionic gonadotropin. No significant effect was found in .a controlled studyZ3”. 
(+) Clofibrate (Atromid S). Competes for sites ia vitro on TBPA and TBA, but not 
TBG233. With doses of z-z.5 g daily, the PBI increased from 5.9 to 7.4 pg/dlzZ4. 
Others report no effect ipz &0235. 
(-) o,p’-DDD. Competes with T4 for sites on TBGZ36. 
(+) Dextrothyroxine (Choloxin). Although metabolically inactive, the dextro isomer 
is detected by all chemical tests211. 
* Abbreviations used : T3, tri-iodothyronine; T4, thyroxine; PBI, protein-bound iodine; CPB, 
competitive protein binding; RAIU, radioactive iodine uptake; TBA, thyroxine-binding albumin; 
TBG, thyroxine-binding globulin; TBPA, thyroxine-binding prealbumin. 
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(0) Diazepam (Valium). No effect after in vivo administrationz37. 
(-) Diazo dyes (Direct Blue, Evans Blue, Niagara Blue, Trypan Blue). Compete for 
T4 binding sites235,238. 
(0) Digitoxin. Given orally, 0.01 mg/kg per week, had no effect on PB?. 
(+) Di-iodohydroxyquin (Floraquin, Diodoquin).’ Absorbed through vaginal mem- 
brane. PBI increased 1-4 pg/dl in half of patients240~241. 
(-) 2,4-Dinitrophenol. Competes with T4 for sites on TBPA but not on TBG or TBA242. 
An antithyroid agentZ3*. 
(-) Diphenylhydantoin (Dilantin). Competes with T, for TBG sites243 but not for 
TBA or TBPA. Increases metabolism of T4 by the live+*+5. 
(-) Disulfiram (Antabuse). Sulfide affects iodine assay. If not completely removed 
following ashing, sulfide complexes with ceric ion214. 
(+) Dithiazanine iodide (Delvex). PBI showed tendency to rise in 6 patients246. 
(+) Estrogens (oral contraceptives, pregnancy). Cause an increase in TBG, thus an 
increase in total Tq247. 
(+) Ether anesthetic. Probably a true change, mechanism unknown24*. 
(0) Fluoridated drinking water249. 
(+) Gallamine triethiodide (Flaxedil)217. 
(-) Gentisate. Competes with T4 for sites on TBPA but not TBGZ50. 
(-) Gold sodium thiosulfate. Gold is bound to protein and excreted very slowly. 
Inhibits the ceric-arsenite reaction, probably by forming iodoauric acid. Gold is 
not removed in the dry ash stepZ51. 
( ?) Hydrochlorothiazide. One study found that the PBI was lowered, possibly due 
to a. true change252. Another study found that the PBI was unchanged21s. 
(+) Iodide (massive doses of potassium iodide) _ Excess inorganic iodine is removed if 
14 washings, rather than 3 or 4, are used. PBI may be elevated as a result of 
iodination of albumin or increased synthesis of di-iodotyrosine253-255. 
(+) Iodinated albuminz41. (Used for plasma volume determination.) 
(+) Iodinated drinking water. PBI is affected only at concentrations greater than 
5 mg/liter256. 
(+) Iodinated glycerol (Organidin). Doses of 125 mg I/day caused an average eleva- 
tion of PBI by 1.1 pg/dl; of zoo mg/day, by 2.0 pg/dlZS7. 
(+) Iodine-containing preparations. Included are topical applications such as anti- 
septics, oral disinfectants, antidandruff preparations, suntan preparations, and 
toothpastes; expectorants, antispasmodics, diuretics, and analgesics; intestinal 
disinfectants, including anthelminthics and amebicides; vitamin-mineral and cod 
liver oil preparations217. 
(+) Iodine, “occult”. Ingestion of drugs whose iodine content has no pharmacologic 
function may remain undiscovered246~258. 
(+) Iodochlorhydroxyquin (Vioform, Clioquinol). A metabolite is bound to protein. 
Eight subjects receiving 500 mg/day showed a mean PBI of 118 ~g/d1226J59. 
(0) Iodophor detergents (occupational exposure to atmospheric contamination by 
laundry workers). No effect on. PBIzSO. 
(+) Iothiouracil (Itrumil). Five patients receiving zoo mg/day showed PBI values of 
63-119 pg/dl. Thyroid function is depressedZ61. 
(-) Isoniazid+$-aminosalicylate (Isopacin). Effect is due to the latter compound221. 
(0) Isopropamide iodide (Darbid, Combid). No definite alteration in PBIZ46. 
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(-) Mercurial diuretics (mercuhydrin, meralluride). Mercuric iodide is formed in the 
digestion and distillation procedures. No effect on dry ash procednre21*J6*. 
(+) ~~~~~ergid~ maleate (Deseril, Sansert). mechanism unknown, probably a true 
263 
(+) Metrecal. Ingestion of I quart per day led to increased PBI values in 6 subjects. 
Contains iodocaseinzR4. 
(0) Metronidazole. Daily dosage of IZOO mg produced no change in one week***. 
(-) Penicillin. Competes for TBPA binding sites***. 
(+) Perphenazine. PBI levels greater than 8 ,&dl noted in 13 of 50 patients**7. 
Iodinated contaminants may become strongly protein bound for some patients***. 
(-) Phenylbutazone (Butazolidin). Probably competes for TBA sites. Has anti- 
thyroid activityzza. 
(+) Povidone-iodine (Betadine). PBI increased by 2.3 pg/dl 24 h after pre-operative 
treatment of vaginal tractz6*. 
(+) Pyrazinamide. Mechanism unknown2?*. 
(+) Radiographic contrast media, iodine containing. These can be grouped according 
to the duration of the interferenceelt~*l*~241~*71. 




Intermediate (6-12 weeks) 
Acetrizoate sodium (Urokon, Cystokon) 
Iopanoic acid (Telepaque) 
Long (more than 12 weeks) 
Iodipamide (Biligrafin, Cholografin) 
Iodized oil (Lipiodol) 
Iodoalphionic acid (Priodax) 
Iophendylate (Pantopaque). 
Iophenoxic acid (Teridax) 
Propyliodone (Dionosil) 
(0) Reserpine. No effect on PBI?. 
(-) Salicylates. Compete for sites on TBPA but not on TBG or TBA*%***,*i*, Sali- 
cylates uncouple oxidative phosphorylation; there is tyue inhibition of thyroid 
activity indirectly via higher centers 1~274--277. An early (15-IZO min) decrease of 
T4 levels results from increased free T4 going to extra-hepatic regions*7*. 
f+) Sulfobromophthalein (BSP). May be contaminated with organic iodine*‘*. 
(-) Sulfonamides. Some sulfonamides compete for binding site+. 
(0) Tetracycline. No effect on PBI in 14 patients receiving z g daily for II days*=. 
(+) Tetraiodofluorescein (Erythrosine). (A pink dye used to color capsules, other 
medicines, foods, and lipsticks)**13***. 
(0) Thiamylal (Surital). No effect on PBI*4*. 
(-) Thiazide diuretics. Mechanism unknown; may involve a true change***. 
(0) Thiopental (Pentothal, thiopentone). No effect on PBI*as. Has marked anti- 
thyroid effect in ratF3. 
(0) Thioridazine (Mellaril). PBI remained unchanged in 6 women given r50 mg/&y 
for 60 daysza4. 
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(-) Tolbutamide. Probably competes for binding sites2%**5. 
(+) Tubing, plastic. One kind of tubing (Bard Intercath), used for intravenous in- 
fusions, contains an aliphatic iodine compound which is washed out and becomes 
protein-boundZa6. 
(0) Warfarin. No effect at doses of 5 mg/day28’?88. 
B. T,-by-cohmn. Serum is acidified with pH 4.0 buffer to dissociate thyroxine 
(T4) from serum proteins, added to an anion exchange column, and washed with acid 
to remove proteins, iodotyrosines, and certain exogenous iodinated compounds. T+ 
iodothyronine (T3) and T4 are quantitatively eluted with concentrated acetic acid; 
iodine is liberated either by alkaline incineration or by direct bromination, and de- 
termined by its catalytic effect on the ceric-arsenite reaction. Inorganic iodide remains 
on the co1umn28g~290. Significant drug interference occurs with substances which affect 
the amount of thyroxine in transport and with certain iodine-containing compounds. 
(-) Aminoglutethimide. Competes for T4 binding site+. 
(-) Androgens, anabolic steroids. Decrease level of TBG, resulting in decreased total 
T4zZ3. 
(-) Barbiturates. Compete with T, for TBPA sites2243325. 
(-) Chlorpropamide. Electrophoresis shows competition for TBG sites231. 
(-) o,p’-DDD. Competes with T, for sites on TBG2s6. 
(+) Dextrothyroxine (Choloxin). Reacts as thyroxine211. 
(0) Diazepam (Valium). No effect in ojz10~~~. 
(-) Diazo dyes. Compete for T4 binding sites225~238. 
(-) a,4-Dinitrophenol. Competes with T, for sites on TBPA but not on TBG or TBA2*2. 
An antithyroid agent230. 
(-) Diphenylhydantoin (Dilantin). Competes with T4 for TBG sites243 but not for 
TBA or TBPA. Increases metabolism of T4 by the liver244y245. 
(+) Estrogens (oral contraceptives, pregnancy). Increase level of TBG, resulting in 
increased total Td24’. 
(-) Gentisate. Competes with T, for sites on TBPA but not TBG250. 
(+) Iodine, organic. Some exogenous organic iodine compounds elute with thyroxine. 
Such cases are usually recognizable by abnormal elution patternszsg. 
(+) Iodoalphionic acid (Priodax). Interferes when using direct bromination of the 
eluatezsO. 
(+) Iopanoic acid (Telepaque). Interferes when using direct bromination of the 
eluateZgO. 
(-) Iothiouracil (Itrumil). Thyroid function is depressedZ61. 
(-) Oxyphenbutazone (Tandearil). We have observed yellow eluates from serum 
of patients receiving the drug. The color persists in the final reaction mixture. 
(-) Penicillin. Competes for TBPA binding sitesz66. 
(-) Phenylbutazone (Butazolidin). Probably competes for TBA sites. Has anti- 
thyroid activityZ22. 
(-) Salicylates. Compete for sites on TBPA but not on TBG or TBAZ%2%273. 
(-) Sulfonamides. Some compete for binding sitesI. 
(-) Tolbutamide. Probably competes for binding sites231y285. 
C. T4 by competitive protein b&d&g (CPB). Ethanol is added to serum to pre- 
cipitate proteins and extract the thyroxine. The alcohol extract is dried, and the residue 
is treated with a standard solution of normal serum in barbital buffer containing radio- 
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iodine-labeled thyroxine. After equilibration, the unbound thyroxine is removed by 
gel filtration or by adsorption on ion exchange resin, and the bound radiothyroxine is 
counted. From the per cent bound ra~othyroxine, the total unlabeled thyroxine is 
found using a standard curve 291~292. Drugs whiich compete for binding sites act to 
decrease the total serum thyroxine level. If, however, the drug is extractable into 
ethanol, subsequent binding to TBG in the standard serum will increase the apparent 
T4 level in the unknown. (Barbital inhibits binding of T4 to TBPA and the serum is 
diluted suf&ciently in the method to minimize binding to TBA). CPB methods are 
considered to be more specific for thyroxine than either the PBI or T,-by-column test. 
(-) Androgens, anabolic steroids. Decrease level of TBG, resulting in a true decrease 
in total TaZZ3. 
(-+) Chlorpropamide. Electrophoresis shows competition for TBG sites29r. Tends to 
decrease total T, but may be extracted by ethanol and cause false increase. 
(i) o,$‘-DDD. Competes with T, for sites on TBG 236. Tends to decrease total T4 but 
may be extracted by ethanol and cause false increase. 
(+) Dextrothyroxine (Choloxin) . Reacts as thyroxine211. 
(-) 2,4-Dinitrophenol. Competes with T4 for sites on TBPA but not on TBG or TBA242. 
An antithyroid agentaso. 
(+) Diphenylhydantoin (Dilantin). Competes with T& for TBG sites but is extracted 
from serum with ethanol and causes false increase in values2*3. 
(+) Estrogens (oral contraceptives, pregnancy). Increase level of TBG, resulting in a 
true increase in total Tq247. 
(-) Gentisate. Tends to decrease total T., but does not bind to TBG2!j0. 
(-) Iothiouracil (Itrumil). Thyroid function is depressed861. 
(-) Penicillin. Tends to decrease total T4 by binding with TBPA but does not bind to 
TBG=. 
(-) Pl~enylbut~one (~utazoli~n). Probably tends to decrease total T4 by binding to 
TBA. Has antithyroid activityza2. 
(-) Salicylates. Tend to decrease total T4 by binding to TBPA, but do not bind to 
TBG211,%42,273 
D. The T, test (msatwated UzyzyroxiPze-b&ding tob&n). Serum is equilibrated 
with radioactive to-iodoth~on~e (T3) in the presence of a resin. The excess T,, ad- 
sorbed by the resin and counted, is inversely related to the concentration of unsaturat- 
ed thyroxine-binding sites. In some methods’the supernatant is counted and expressed 
as unsaturated thyroxine-binding capacity or index of normal. In the tabulation be- 
low, we express results as T,uptake by resin; thus, high ?; values are found in hyper- 
thyroidism and low T3 values in hypothyroidism. Drug interferences include sub- 
stances which produce an alteration in the total number of binding sites and drugs 
which compete with T, for the available sites. Factors affecting the T3 test have been 
reviewed by SissonZg3. 
(+) Aminoglutethimide. Competes for binding sitesI. 
(+) Androgens, anabolic steroids. Decrease level of TBG”x3. 
(+) Barbiturates. Compete for TBPA sites”24p225. 
(+) Chlorpropamide. Competes for TBG sites. T3 resin results were increased pro- 
portional to level with in V&O addition and increased IO-30% with 30 mgikg 
administered intravenous1yZ31. 
(0) Clomiphene. Daily administration of IOO mg had no effect on the t&294. 
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(+) o,$‘-DDD. Competes for sites on TBGss6. 
(+) Dextrothyroxine (Choloxin). Binds to usual T, binding sites, thus decreasing un- 
saturated TBGZll. 
(0) Diazepam (Valium). No effect after in viva administrationz37. 
(+) Diazo dyes. Compete for binding sites2”5,2”*. 
(+) Dicumarol and other coumarins. Compete with T3 for TBA sites21%295. 
(+) 2,4-Dinitrophenol. Competes for sites on TBPAZ*z. 
(+) Diphenylhydantoin (Dilantin). Competes for TBG sites but not for TBA or 
TBPA243. No effect was noted, however, after administration of 300 mg/day for 
I weekZs6. 
(-) Estrogens (oral contraceptives, pregnancy). Increase levels of TBG247. 
(+) Gentisate. Competes for sites on TBPA but not TBGZ50. 
(+) Heparin. Competes with T3 for TBA sites 211. Also causes a transient significant 
elevation of free Tqzg7. 
(-) Iothiouracil (Itrumil). Thyroid function is depressedZ61. 
(+) Ipodate (Uragrafin). A significant increase has been reported, which appears to 
be unrelated to iodine content211~298. 
(0) Metronidazole. Daily dosage of IZOO mg produced no change in one week265. 
(+) Penicillin. Competes for TBPA sitesY. 
(+) Phenylbutazone. Probably competes for TBA sites299. 
(0) Povidone-iodine (Betadine)269. 
(+) Salicylates. Compete for sites on TBPA, but not on TBG or TBAZ11,242,Z’i3. 
(+) Sulfonamides. Some compete for binding sites?. 
(0) Tetracycline. No effect on test in 14 patients receiving 2 g/day for II daysz80. 
(0) Thiamylal (Surital). No effect on testZ4*. 
(0) Thiopental (Pentothal, thiopentone). No effect on test248. 
(+) Tolbutamide. T, resin results were increased proportional to level with in v&o 
addition and increased 510% with I g administered intravenously231. 
(0) Warfarin. No effect at doses of 5 mg/day287~288. 
E. Radioactive iodine uptake (RAIU). Radioactive iodide is administered and, 
after the desired interval (usually 24 h), thyroidal radioactivity is measured by an 
external scintillation counter and expressed as a percentage of a standard sample 
measured in an identical manner. Factors influencing the test have been reviewed by 
GraysonZZO and by Magalotti et al. So0 Interferences are produced by drugs which alter . 
the size of the iodine pool, including iodinated organic compounds as well as inorganic 
iodine. The-effect of iodinated organic compounds is related to metabolic processes 
which result in continual release of inorganic iodine such as occurs following adminis- 
tration of iodinated radiographic contrast media. Drugs which displace thyroxine 
from its carrier proteins, producing an increase in free thyroxine, can cause a tempo- 
rary decrease in thyroidal uptake of iodine due to suppressed thyroxine synthesis. 
(0) Acetazolamide. Drug produces no effect on test218. 
(-) p-Aminobenzoate. Antithyroid activity has been suggestedz19. 
(-) $-Aminosalicylate. Antithyroid activity has been suggested220-2Z2. 
(-) Barium sulfate. Sometimes contaminated with iodine sufficient to raise the PBI, 
hence could enlarge the total iodine ~001~~~. 
(-) Bromides. Some preparations contain iodide as a contaminantzZO. 
(0) Calcium. Calcium loading and subsequent withdrawal had no effect in 7 subjects2?*. 
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(-) Chlorpheniramine (Chlor-Trimeton), antihistamine preparations. One 4-mg 
tablet 4 times/day reduced RAIU to 52% of original in 52 euthyroidF. 
(+) Chlorpromazine-procyclidine. Volunteers receiving the drugs in combination 
showed 24-h RAIU of 39.7% compared to controls of 30.2%. Renal iodine 
clearance (2-3 h) was decreased from 45.2 to 27.4 ml/min30Y. 
(-) Clofibrate (Atromid S). Doses of 2-2.5 g/day resulted in decreased RAIU. The 
mechanism appears to be a displacement of T4 bound to protein with transient 
increase in free T4 and depression of thyroid function. The effect lasts 0.5-4 
months, after tihich pretreatment values are regainedz34. 
(0) Diazepam (Valium). No effect after in vivo administration237. 
(0) Digitoxin. Drug given orally, 0.01 mg/kg per week, had no effect on RAIU239. 
(-) Dithiazanine iodide (Delvex). RAIU depressed below normal range in 6 patients2t6. 
(0) Hydrochlorothiazide. No change in RAIU218~252. 
(-) Indocyanine Green. Contains ,about 5% sodium iodide as a contaminant. Causes 
significant suppression, particularly for hyperthyroid individualsso2. 
(-) Iodide (Massive doses of potassium iodide). Increases size of iodine pool. 
(-) Iodinated d r-in k ing water. In concentrations of I mg/liter (level used for dis- 
infecting), RAIU is depressedzSG: 
(-) Ipoo;;;d glycerol (Organidin). Daily dosage may contribute 125-200 mg iodine 
257 
(-) Iodine-containing preparations. See examples under PB1217. 
(-) Iodine, inorganic. Preparations containing small doses reduce the thyroidal up- 
take without affecting the PB12469303. Iodine and iodate, added to bread, may 
also cause individual or regional variations in RAIU304. Ingestion of drugs whose 
iodine content has no pharmacologic function may remain undiscovereda58. 
(-) Iodine, organic. Metabolism of organic iodine compounds may raise the plasma 
inorganic iodine leve1215. This category includes iodinated radiographic contrast 
media. 
(-) Iothiouracil (Itrumil). Thyroid function is depressedz61. 
(-) Isoniazid+$-aminosalicylate (Isopacin). Effect is due to the latter compound221. 
(-) Isopropamide iodide (Darbid, Combid). Significant decrease in RAIU in 8 of g 
subjects246. 
(0) Mercurial diuretics. No effect on 6-h and 24-h RAIU in 8 euthyroid subjects305. 
Another report suggests that diuretics given at the time of the test may depress 
uptake values whereas after prolonged diuresis the RAIU may be elevated300. 
(-) Methantheline bromide (Banthine). Reported to decrease test results299. 
(0) Metronidazole. Daily dosage of 1200 mg produced no change in one week”65. 
(-) Perphenazine. RAIU depressed306. 
(-) Phenylbutazone. Has antithyroid activity 222. In 13 euthyroid patients receiving 
800 mg/day for 4 days, the RAIU fell to 20-30~~ of control values307. 
(-) Radiographic contrast media, iodine-containing. Metabolism raises the inorganic 
iodine pool. See list and duration of interference under PBI. 
(0) Reserpine. No effect on RAIU272. 
(-) Resorcinol. Used in ointments and may be absorbed through the skin. Probably 
an antithyroid agentZZO. 
(0) Salicylates. Test is not affectedsoB. 
(0) Tetracycline. No effect on RAIU in 14 patients receiving 2 g/day for II dayP". 
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(-) Vitamin A. Seven subjects were given 50000 IU orally per day for 21-27 days. 
The 24-h RAW ranged from ~~-68% before administration, and decreased to 
14-32% after administration, of the vitamin3~9. 
TRANSAMINASE (GOT) 
Serum glutamic oxaloacetic transaminase (GOT) catalyzes transfer of an amino 
group from aspartate to cc-ketoglutarate with formation of oxaloacetate and glutamate. 
Oxaloacetate is measured colo~met~cally after reaction with 2,4-~nitrophenyl- 
hydrazine or various azo dyes. For kinetic measurements, the reaction is coupled with 
NADH in the presence of malic dehydrogenase and the rate of disappearance of NADH 
is measured at 340 nm. Except as noted, the following refer to results obtained with 
the current method on the Technicon SMA 12160 in which oxaloacetate is dialyzed 
and reacted with Fast Ponceau L (diazotized ~-butyl-4-methoxymetaniIamide) ac- 
cording to Morgenstern et al. 310. The upper limit of normal is 40 units. 
(+) Acetaminophen (APAP) ll. Pure solution of the drug reported to produce color 
with the dye. 
(+) Acetoacetic acid 31L@2. Reacts with the dye to produce color and causes spurious 
elevation of GOT in patients with ketosis. Acetone and P-hydroxybutyric acid 
do not react. A solution containing 8.3 mg/dl increased the apparent GOT by 
38 unit+%. No interference was encountered in the ultraviolet method nor with 
other coupling reagents tested312. 
(+) +Aminosalicylatexl. Pure solution of the drug reported to produce color with the 
dye. 
(+) Ascorbic acid 11. A solution containing 250 ,ug/ml produced color equivalent to 
32 units. The usual concentration of ascorbic acid in serum is about IO fag/ml at 
which level interference would be negligible. 
(+) Erythromycin 314. Apparent GOT activity is elevated when either dinitrophenyl- 
hydrazine or a diazonium salt, azoene fast violet B, is used as color developer. 
The interfering substance is presumably a metabolite since erythromycin itself 
does not react. No interference was found with the ultraviolet kinetic method. 
(+) IsoniazidZI. A solution containing 3.2 pg/ml produced color equivalent to IO units. 
(+) Levodopall. A solution containing 20.8 pg/ml produced color equivalent to 33 
units. With usual therapeutic doses, plasma levels rarely exceed 4 pg/ml. 
(+) Methyldopa 11 A solution containing 62.5 ,ug/ml produced color equivalent to .
16 units. With usual therapeutic doses, plasma levels rarely exceed 3 pg/ml and 
interference should be negligible. 
UREA NITROGEN 
A. Reaction of wea with diacetyl monoxime wtdev acid conditions to produce a 
yellow color (Fewon reaction). Thiosemicabazide may be included in the reagent. 
(-) Sodium azide315. May be added to serum as a preservative. At a concentration of 
roe mgjdl, serum urea was reduced from 50 to an apparent 19 mgjdl. 
(+) Substituted ureas. Absorbance, relative to urea, has been reported as follows31@: 
Citrulline I.5 
Hydantoin 0.3 
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Methylurea 1.5 
Phenylurea 2.2 
Sulfonylureas, and other compounds containing the ureido group, should also 
react317. 
B. Serum is incubated with urease to relase ammonia from wea. Ammonia is then 
measured with the phenol-hypochlorite reaction. Phenol reagent must be added be- 
fore hypochlorite; otherwise, deamination of various compounds can occur and lead 




Both compounds are reported to inhibit color development318. 
C. Incubation with urease to release ammonia followed by color development with 
Nesslev’s reagent. 
(+) Acetone 320. Turbidity is produced at levels frequently encountered in diabetic 
acidosis. 
(+) Chloral hydrate 321. A rise of 4-6 mg/dl in apparent blood urea nitrogen values 
occurred 90 min after oral administration of 3 g of chloral hydrate. 
(+) Creatinine3zo. Elevated levels introduce a small positive error. Effect is minimized 
by reading absorbance at I min after Nesslerization. 
D. Reaction qf uuyea with dimethylaminobenzaldehyde in acidijed ethanol to pro- 
duce a yellow-green color. 
(+) p-Aminosalicylate 322. Produces similar color. 
(+) Dextran 323~324. Turbidity formation, owing to precipitation of dextran by ethanol. 
(+) Sulfonamides322+5. Produce similar color. 
URIC ACID 
Methods for the determination of uric acid have been reviewed recently by 
Martinek3Z6. The enzymatic procedure of Liddle et a1.327, is generally recognized as a 
suitable reference method. 
A. Reduction of phosphotungstate by wate in alkaline solution to produce a blue 
color. Most of the following substances, or their metabolites, interfere as reducing 
agents. 
(+) Ascorbic acid. In a carbonate-phosphotungstate method, I mg of ascorbic acid 
produced color equivalent to 1.3 mg of uric acid328. This interference can be 
eliminated by preliminary treatment of serum or protein-free filtrates with dilute 
alkali. 
(+) Caffeine. Metabolites of caffeine and theophylline include methyl-substituted 
uric acids which act as reducing agents 329y330. One g of caffeine or theophylline per 
day increased the urinary non-urate chromogens from about 40 mg (low purme 
diet) to 400 mg/day. Concentrations of the metabolites in plasma are probably 
negligible. 
(-) Chlorine. May be present as an impurity in distilled water. Forms hypochlorite 
which oxidizes urate in alkaline solution331. 
(+) Ergothioneine. Present in red blood cells but not in plasma. Interferes if serum is 
hemolytic. 
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(+) Gentisic acid. See salicylate. 
(+) Glutathione. Present in red blood cells but not in plasma. Interferes if serum is 
hemolytic. 
(+) Levodopa. When given in doses of 3-7 g/day, apparent serum uric acid was falsely 
elevated by an average of 2076 and apparent urine uric acid was increased to 
2-4 times the upper limit of normal. A dilute aqueous solution produced color in 
the reaction332. The ultraviolet method for uric acid was not affected. 
(+) Methyldopa. With usual oral dosage, plasma concentrations are negligible (z-3 
pg/ml) but urinary excretion may amount to 250 mg/day8. We have observed 
that an aqueous solution of IO mgidl produced a color equivalent to approximate- 
ly IO mg/dl of uric acid with the carbonate-phosphotungstate method. 
(+) Phenacetin Il. Ingestion of 2 g of phenacetin or its metabolite, N-acetyl-p-amino- 
phenol, increased apparent plasma uric acid by approximately I mg/dl after 2 
to 4 h. Apparent concentration of uric acid in urine was increased z-fold. 
(+) Potassium ion. Produces turbidity with alkaline phosphotungstate. Plasma con- 
taining potassium salts of anticoagulants is unsuitable for uric acid determina- 
tions. 
(+) Salicylate. Gentisic acid, a metabolite, acts as a reducing agent383. Relatively 
high concentrations appear in urine but not in plasma. However, high concentra- 
tions of uricase-resistant chromogens have been noted in serum from patients 
with gout whose serum salicylate was maintained near 30 mg/d1334. 
(+) Theophylline. See caffeine. 
B. Methods de$endi;iP?g on action of z&case. 
(-J) Formaldehyde (formalin). Inhibits uricase activiQ+. Leads to low results if 
formalin is added as a preservative to specimens. False high results may be ob- 
tained if unknowns are compared to standards containing formalin. 
UROBILTNOGEN (URINE} 
Urobilinogen reacts with p-dimethylaminobenzaldehyde in acid solution (Ehr- 
lich’s aldchyde reagent) to produce a red color. Sodium acetate is added to reduce 
acidity, to intensify the color, and to inhibit color formation from indole. Porpho- 
bilinogen also reacts but will remain in the aqueous layer, in contrast to urobilinogen, 
after extraction with chloroform 336. An additional extraction with butanol is claimed 
to remove all of the known Ehrlich aldehyde compounds, except porphobilinogen, and 
forms the basis of a highly specific test for the latte?‘. 
(+) p-Aminosalicplate 338. Urine from patients receiving this drug produces a red 
color with the reagent. 
(+) Bilirubin. Forms a green color under the reaction conditions and should be 
removed by treating the urine with barium chloride prior to performing the test. 
(+) Chlorophyl1339. A metabolite, phylloerythrinogen, forms a dark red condensation 
product with the reagent. 
(+) Chlorpromazine340. May lead to increased values for urobihnogen, in the absence 
of jaundice. 
(+) 5-Hydroxyindofeacetic acid 3g6+1. Produces a bluish-pink color with the rea- 
gent. 
(+) Indolc+*. Present in normal urine and produces an orange-brown color with the 
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reagent. Interference is minimized by adding acetate immediately after mixing 
urine with the reagent. 
(+) Phenazop~~ne (Py~dium}$. Colors urine orange-brown and becomes reddish- 
brown in acid solution. 
(+) Radiographic contrast media. Diatrizoate (Hypaque) produces a heavy yellow 
precipitate with the reagenF and iopanoic acid (Telepaque), a white cloudy 
precipitate342. Both compounds are precipitated in acid solution. 
(-) Smog343. Spots on paper chromatograms are reported to be destroyed, presumably 
due to oxidation by ozone. 
(+) Sulfonamides336~33*~3~l. Those containing a free amino group produce a greenish- 
yellow color with the reagent. 
VANILMANDELIC ACID (VMA) 
A. Smeeni?zg tests OTZ W&W are based on the reaction with diazotized p-nitro- 
aniline to produce a purple color which is extracted into a-amyl alcohols**. Such meth- 
ods lack specificity and results can be misleading. More elaborate extraction and 
purification are claimed to improve specificity345. 
(+) $-Aminosalicylic acid. Produces color with diazo reagent346. 
(+) Anileridine3*‘. 
(+) Bananas. Apparent elevation owing to increased excretion of j-HIAA (see below). 
(+) 5-Hydroxyindoleacetic acid 348. Elevation in apparent VMA is directly propor- 
tional to the concentration of 5-HIAA. 
(+) Methenamine mandelate (Mandelamine) l. Reported to produce a similar color. 
(+) MethocarbamoP47. 
(+) Phenolsulfonphthalein (PSP). Can result in color if not completely extracted346. 
3. ~u~~t~~~~~~~~ o~e~~~e of Pisnno, based on extraction, purification, oxidation 
to vanillin. and measurement of absorbance at 360 nm3*s. 
(-) Clofibrate35°. The glucuronide moiety of the excreted conjugate competes for 
periodate in the oxidation step. This can be overcome by increasing the concentra- 
tions of periodate and metabisulfite 5-fold. 
(0) _~etllyldopa351. No interference was observed in Pisano’s method. 
(+) Nalidixic acid35Z. The free acid shows significant absorbance at 360 nm. Apparent 
urinary excretion of VMA may be increased up to +fold on usual therapeutic 
regimens. 
(0) Vanillin353. Dietary vanillin, up to 62 mg/day, was shown to have no effect on 
VMA values obtained by Pisano’s method. 
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Iodine uptake. See thyroid function tests. 
Ketone bodies (urine) 










Protein-bound iodine. See thyroid function tests. 
Prothrombin time 
PSP test 
Specific gravity (urine) 
T, and T4 tests. See thyroid function tests. 
Thymol turbidity 
Thyroid function tests 
Protein-bound iodine 
T,-by-column 
T4 by CPB 
T3 test 
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